Pharmaceutisch Weekblad

, Volume 11, Issue 6, pp 224–228 | Cite as

Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models

  • C. M. A. Rademaker
  • R. W. Jones
  • L. J. Notarianni
  • A. van Dijk
  • J. H. Glerum
  • J. Verhoef
Original Articles


The pharmacokinetics of ofloxacin following a single 200 mg oral dose were studied in twelve healthy elderly volunteers. Relevant pharmacokinetic parameters were analysed by both noncompartmental and compartmental models. In compartmental analysis, the data on plasma concentrations was best described by an open two-compartment model. A zero-order absorption behaviour was found in some volunteers. The terminal half-lives were slightly prolonged and ranged from 6.2–11.6 h. A linear relationship was found between the renal clearance of the drug and the estimated creatinine clearance. Computer predictions of a multiple 200 mg dose regimen showed no important accumulation of ofloxacin. The recommendation of some authors that, in general, ofloxacin dosage may be halved in the elderly could not be confirmed. This has to be determined through further clinical experience in elderly ill subjects.


Absorption Aged Clearance, renal Models, theoretical Ofloxacin Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Neu HC. Clinical use of the quinolones. Lancet 1987;2:1319–22.PubMedGoogle Scholar
  2. 2.
    Monk JP, Campoli-Richards DM. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987;33:346–91.PubMedGoogle Scholar
  3. 3.
    Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother 1987;31:156–60.PubMedGoogle Scholar
  4. 4.
    Bell JA, May FE, Stewart RB. Clinical research in the elderly: ethical and methodological considerations. Drug Intell Clin Pharm 1987;21:1002–7.PubMedGoogle Scholar
  5. 5.
    Elseviers MM, Verpooten GA, De Broe ME. Interpretation of creatinine clearance. Lancet 1987;1:457.PubMedGoogle Scholar
  6. 6.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;6:31–41.Google Scholar
  7. 7.
    Notarianni LJ, Jones RW. Method for the determination of ofloxacin, a quinolone carboxylic acid antimicrobial, by high-performance liquid chromatography. J Chromatogr 1988;431:461–4.PubMedGoogle Scholar
  8. 8.
    Lode H, Höffken G, Olschewski P, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987;31:1338–42.PubMedGoogle Scholar
  9. 9.
    Benet LZ. Mean residence time in the body versus mean residence time in the central compartment. J Pharmacokinet Biopharm 1985;13:555–8.PubMedGoogle Scholar
  10. 10.
    Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 1982;71:372–3.PubMedGoogle Scholar
  11. 11.
    Grevel J, Nüesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986;31:211–6.PubMedGoogle Scholar
  12. 12.
    Hespe W, Verschoor JSC, Olthoff M. Bioavailability of new formulations of amoxicillin in relation to its absorption kinetics. Arzneimittelforsch/Drug Res 1987;37:372–5.Google Scholar
  13. 13.
    Gibaldi M, Perrier D. Pharmacokinetics. 2th ed. New York: Marcel Dekker Inc. 1982.Google Scholar
  14. 14.
    Veyssier P, Fourtillan JB, Modai J, et al. Pharmacocinétique de l'ofloxacine chez le sujet agé (65 à 85 ans) à fonction rénale normale après prise oral unique de 200 mg. Pathologie Biologie 1986;34:569–99.Google Scholar
  15. 15.
    Graber H, Ludwig E, Arr M, Lányi P. Difference in multiple-dose pharmacokinetics of oflaxacin in young and aged patients. International Symposium on new quinolones, Geneva, 1986 [Abstract].Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • C. M. A. Rademaker
    • 1
  • R. W. Jones
    • 3
  • L. J. Notarianni
    • 3
  • A. van Dijk
    • 2
  • J. H. Glerum
    • 2
  • J. Verhoef
    • 1
  1. 1.Department of Clinical Microbiology and Laboratory of Infectious Diseases and U-Gene ResearchUniversity HospitalGA Utrechtthe Netherlands
  2. 2.Department of Hospital PharmacyUniversity HospitalUtrecht
  3. 3.Research Institute for the Care of the ElderlySt. Martins HospitalBathEngland

Personalised recommendations